Rapid, accessible, globally distributed RNA vaccine manufacture on demand

人类面临的最大挑战之一是消除传染病的生存威胁，包括人畜共患流行病，如未来疾病X的威胁。英国有一个千载难逢的机会，可以通过其COVID19投资创造长期遗产，建立一个世界领先的产业，使人类能够以环境可持续和经济可行的方式减轻甚至消除传染病。疫苗是现代医学的伟大成功故事之一，根除或控制了许多具有重大全球重要性的严重感染，并改善了数百万人的生活。然而，尽管在开发合成RNA疫苗等新疫苗技术方面取得了重大进展，但COVID19已经证明了传统疫苗制造方法的许多挑战和低效，阻碍了数百万人在全球快速获得疫苗。BiologIC Technologies带来了颠覆性的工业4.0技术，使分布式端到端生物制造成为可能。我们的目标是建立一种医疗技术，按需快速、经济、环境可持续、全球分布、端到端的RNA疫苗制造。该系统将大幅降低疫苗成本，并将柔性制造分配给快速发展的供应链中的任何需要点。该系统的灵感来自于快速横向生产的计算机体系结构。该系统内的实质性创新包括3D打印生物处理器在连续制造中的新应用，由集成过程分析技术实现的显著降低疫苗成本的新生物工艺流程，以及为分布式生产实施的颠覆性技术。该项目的特别好处包括通过为世界各地不同社会经济群体的需求提供负担得起和公平的疫苗获得机会，减少传染病死亡和疾病。该项目将在前景看好的RNA疫苗领域带来直接的商业利益，创造COVID19疫苗遗产，并使英国成为这一新的合成生物学行业的全球领先者。

One of the greatest challenges faced by humanity is to eliminate the existential threat of infectious diseases including zoonotic pandemics such as the threat of a future Disease X. The UK has a once-in-a-generation opportunity to create a long-term legacy from its COVID19 investments to build a world-leading industry that allows humanity to mitigate, or even eliminate, infectious diseases in an environmentally sustainable and economically accessible manner.Vaccines are one of the great success stories of modern medicine, having eradicated or controlled many severe infections of major global importance and improved the lives of millions. However, whilst significant progress has been made in developing new vaccine technologies such as synthetic RNA vaccines, COVID19 has demonstrated the many challenges and inefficiencies of classical vaccine manufacturing approaches, preventing rapid global access by millions of people.BiologIC Technologies brings disruptive industry 4.0 technology that enables distributed end-to-end biomanufacturing. The objective is to build a medical technology for rapid, economically accessible, environmentally sustainable, globally distributed, end-to-end RNA vaccine manufacture on demand.The system will substantially reduce vaccine costs and distribute flexible manufacturing to any point of need in the rapidly evolving supply chain. The system is inspired by computer architectures for rapid scale out production.Substantial innovations within the system include the novel application of 3D-printed bioprocessors in continuous manufacturing, new bioprocess flows enabled by integrated Process Analytical Technology to significantly reduce vaccine cost and implementation of a disruptive technology for distributed manufacture.Supported by Centre for Process Innovation, who will advise on mRNA vaccine constructs and bioprocesses, particular benefits of this project include reducing deaths and illness from infectious diseases by providing affordable and equitable access to vaccines by people of diverse socio-economic groups on demand around the world. The project will deliver direct commercial benefit in the promising field of RNA vaccines, creating a COVID19 vaccine legacy and establishing the UK as a global leader in this new synthetic biology industry.